<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CV-159, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic++ + acid <z:chebi fb="36" ids="29309">methyl</z:chebi> 6-(5-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-3-pyrazolyloxy)<z:chebi fb="0" ids="24593">hexyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi>, is a <z:chebi fb="0" ids="50075">dihydropyridine</z:chebi> derivative that blocks the L-type <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel and inhibits the calmodulin (CaM)-dependent pathway </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we examined the effects of CV-159 on rat ischemic brain injury </plain></SENT>
<SENT sid="2" pm="."><plain>CV-159 (5 and 10 mg/kg, p.o.) gave significant protection against delayed neuronal <z:hpo ids='HP_0011420'>death</z:hpo> in the hippocampal CA1 region after 15-min transient forebrain <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast, the <z:chebi fb="0" ids="29108">Ca2+</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi> nicardipine (1 and 10 mg/kg, p.o.) and <z:chebi fb="1" ids="7565">nifedipine</z:chebi> (1 mg/kg, i.p.) and the CaM <z:chebi fb="68" ids="48706">antagonist</z:chebi> N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide (W-7, 500 ng, i.c.v.) had no effect on this hippocampal neuronal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>CV-159 also diminished the size of the brain <z:mpath ids='MPATH_124'>infarct</z:mpath> after permanent middle cerebral artery (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion, although physiological variables, including regional cerebral blood flow, were not affected </plain></SENT>
<SENT sid="5" pm="."><plain>The increase in the water content of the infarcted cortex induced by <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion was significantly reduced by CV-159 </plain></SENT>
<SENT sid="6" pm="."><plain>On the other hand, neither nicardipine nor <z:chebi fb="1" ids="7565">nifedipine</z:chebi> affected the brain <z:mpath ids='MPATH_124'>infarct</z:mpath> size, volume or increased water content induced by <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion, as previously reported (A </plain></SENT>
<SENT sid="7" pm="."><plain>Sauter and M </plain></SENT>
<SENT sid="8" pm="."><plain>Rudin, Am </plain></SENT>
<SENT sid="9" pm="."><plain>J </plain></SENT>
<SENT sid="10" pm="."><plain>Hypertens </plain></SENT>
<SENT sid="11" pm="."><plain>4 121S-127S, 1991) </plain></SENT>
<SENT sid="12" pm="."><plain>These findings indicate that <z:chebi fb="0" ids="29108">Ca2+</z:chebi> <z:chebi fb="68" ids="48706">antagonists</z:chebi>, such as nicardipine and <z:chebi fb="1" ids="7565">nifedipine</z:chebi>, and W-7 have no effect on rat ischemic brain injury </plain></SENT>
<SENT sid="13" pm="."><plain>The results suggest that CV-159 protects against ischemic brain injury </plain></SENT>
<SENT sid="14" pm="."><plain>This might be mediated by both blocking the L-type <z:chebi fb="0" ids="29108">Ca2+</z:chebi> channel and inhibiting CaM-dependent function via <z:chebi fb="0" ids="29108">Ca2+</z:chebi>/CaM binding at a different binding site from that of W-7 to CaM (H </plain></SENT>
<SENT sid="15" pm="."><plain>Umekawa, K </plain></SENT>
<SENT sid="16" pm="."><plain>Yamakawa, K </plain></SENT>
<SENT sid="17" pm="."><plain>Nunoki, N </plain></SENT>
<SENT sid="18" pm="."><plain>Taira, T </plain></SENT>
<SENT sid="19" pm="."><plain>Tanaka, and H </plain></SENT>
<SENT sid="20" pm="."><plain>Hidaka, Biochem </plain></SENT>
<SENT sid="21" pm="."><plain>Pharmacol </plain></SENT>
<SENT sid="22" pm="."><plain>37 3377-3381, 1988) </plain></SENT>
</text></document>